NTT
28.6.2022 06:02:14 CEST | Business Wire | Press release
NTT Ltd. , a leading IT infrastructure and services company, is using technology and innovation to equally enhance the fan experience across both the Tour de France and the Tour de France Femmes avec Zwift.
The 2022 event will see the inaugural women’s race which will start on the Champs-Élysées on July 24th 2022, prior to the conclusion of the men’s race on the same day. The women’s race will feature 24 teams of six riders and will conclude on July 31st 2022 in La Super Planche des Belles Filles. NTT has been the official technology partner of the Tour de France for the past eight years.
For the first time ever, and at a time when interest in women’s cycling is on the rise, NTT will bring fans closer to the action and shine a light on this notable occasion through the implementation of real-time tracking of the riders, the Race Center and its predictive modelling strategy to support the race. The model also includes @letourdata , the data-driven content channel that helps tell the race’s stories over social media and broadcast. Rider and team profiles will uncover unique insights into the women’s pro peloton.
In addition to this, NTT alongside A.S.O. will deliver a host of new and enhanced digital experiences to engage fans around the world, both at home and along the roadside. These experiences include:
- The Digital Human: NTT has developed an interactive kiosk featuring an AI-generated realistic human avatar, trained on the relevant race and tourist information. This technology will be deployed at the official fan store at the Grand Depart in Copenhagen and in NTT’s Technical Truck at the end of every stage.
- An enhanced digital twin : Last year, NTT created a digital twin of the event, which enabled staff to gain real-time visibility and ultimately streamline operations to ensure the continuity and resilience of the race. This year, the technology has enhanced connectivity to provide smarter event operations, enabling quicker, more informed decisions in a highly complex and ever-changing environment.
- Strava partnership: NTT’s live storytelling channel, @letourdata, in collaboration with Strava, will be bringing real-time comparisons between amateurs, pros, and King of the Mountain (or fastest known times) to social media and broadcast during the race.
“With female cycling on the rise as we saw through the 2020 edition of La Course by Le Tour de France avec FDJ with over 30 million TV audience viewers, we’re incredibly proud to continue to help widen the fan base and be part of this historic milestone for female cycling. There is still much more work to be done to achieve equality in cycling, but we’re extremely passionate about doing what we can to increase the accessibility of the sport. Our technology means we can bring the action to more fans than ever before,” says Michele McGuire, Vice President of Managed Services Delivery, Europe at NTT Ltd.
“When it comes to the technology, both races are highly dynamic and require access to real-time information to ensure continuous and smooth operations while creating more informed and engaged fans. NTT’s full stack of solutions and expertise will continue to support the A.S.O. in transforming the famous race,” McGuire adds.
“At A.S.O., we’re extremely proud to be launching Tour de France Femmes avec Zwift and to be able to count on key technical partners such as NTT. Our partnership with NTT is well known for bringing the fans closer to the action. 2022 marks a momentous occasion for women’s cycling, and fans around the world are extremely excited to witness the first edition of the Tour de France Femmes avec Zwift,” said Julien Goupil, Media & Partnerships Director at A.S.O..
NTT’s role as the official technology partner to Tour de France Femmes avec Zwift, means NTT will now support A.S.O. at four of its female events, including Paris-Roubaix Femmes avec Zwift, Flèche Wallonne Femmes, and Liège-Bastogne-Liège Femmes. To find out more about how NTT supports A.S.O., visit: https://services.global.ntt/tourdefrance
Follow @letourdata on Twitter and look for NTT’s race predictions using #NTTPredictor.
ENDS
About Amaury Sport Organisation
Amaury Sport Organisation is a company that owns, designs and organises top international sporting events. Specialised in the ‘non-stadia’ events, it has in-house knowledge of professions linked to organisation, media and sales of sports events. A.S.O. organises 250 days of competition per year, with 90 events in 30 countries. A.S.O. is involved in 5 major sports including cycling with the Tour de France, motor sports with the Dakar, mass events with the Schneider Electric Marathon de Paris, golf with the Lacoste Ladies Open de France and sailing with production and distribution of images for prestigious races. Amaury Sport Organisation is a subsidiary of the Amaury Group, media and sport group that owns the newspaper L’Équipe.
About NTT Ltd.
NTT Ltd. is a leading IT infrastructure and services company. With revenues of over USD 10 billion, we operate in more than 200 countries and regions, and serve 5,000 clients across multiple industries. Through technology and innovation, we deliver a secure and connected future that empowers our people, clients and communities. We lay the foundation for organizations’ edge-to-cloud networking ecosystem, simplify the complexity of their workloads across multicloud environments, and innovate at the edge of their IT environments, where networks, cloud and applications converge. On the journey towards a software-defined future, we support organizations with platform-delivered infrastructure services. As part of the global NTT Corporation, we serve 65% of the Fortune Global 500 and 80% of the Fortune Global 100. We enable a connected future.
Visit us at services.global.ntt
View source version on businesswire.com: https://www.businesswire.com/news/home/20220627005681/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom